Patents by Inventor Prashant Girinath

Prashant Girinath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Airway medicaments
    Patent number: 11654165
    Abstract: Described herein are compositions, methods, kits and devices for the treatment and/or prevention of a wide spectrum of disease conditions. In particular, bacterial populations described herein are live, purified bacteria for the modulation, restoration and/or promotion of the microbiome in the upper respiratory tract of a subject, including the nasal cavity, to promote health. Such bacterial populations may include single or multiple strains for bacteria. The multiple strains of bacteria may be strains from the same or different species, including species of Corynebacterium and/or Dolosigranulum pigrum.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: May 23, 2023
    Assignee: Trench Therapeutics, Inc.
    Inventors: David S. Harburger, Prashant Girinath
  • AIRWAY MEDICAMENTS
    Publication number: 20220072072
    Abstract: Described herein are compositions, methods, kits and devices for the treatment and/or prevention of a wide spectrum of disease conditions. In particular, bacterial populations described herein are live, purified bacteria for the modulation, restoration and/or promotion of the microbiome in the upper respiratory tract of a subject, including the nasal cavity, to promote health. Such bacterial populations may include single or multiple strains for bacteria. The multiple strains of bacteria may be strains from the same or different species, including species of Corynebacterium and/or Dolosigranulum pigrum.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 10, 2022
    Inventors: David S. Harburger, Prashant Girinath
  • AIRWAY MEDICAMENTS
    Publication number: 20220072066
    Abstract: Described herein are compositions, methods, kits and devices for the treatment and/or prevention of a wide spectrum of disease conditions. In particular, bacterial populations described herein are live, purified bacteria for the modulation, restoration and/or promotion of the microbiome in the upper respiratory tract of a subject, including the nasal cavity, to promote health. Such bacterial populations may include single or multiple strains for bacteria. The multiple strains of bacteria may be strains from the same or different species, including species of Corynebacterium and/or Dolosigranulum pigrum.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 10, 2022
    Inventors: David S. Harburger, Prashant Girinath
  • CD40 TARGETED PEPTIDES AND USES THEREOF
    Publication number: 20220048948
    Abstract: The present disclosure is related to compositions comprising peptides that bind CD40 and methods of use in inhibiting interaction of CD40 and CD154 and inducing immunosuppression. Provided herein are methods of transplantation and methods of inhibiting donor specific immune response. Also provided herein are methods of treatment for autoimmune diseases, inflammatory diseases and cancer.
    Type: Application
    Filed: July 20, 2021
    Publication date: February 17, 2022
    Inventors: Bernhard J. HERING, Sabarinathan RAMACHANDRAN, Prashant GIRINATH
  • CD40 targeted peptides and uses thereof
    Patent number: 11130783
    Abstract: The present disclosure is related to compositions comprising peptides that bind CD40 and methods of use in inhibiting interaction of CD40 and CD154 and inducing immunosuppression. Provided herein are methods of transplantation and methods of inhibiting donor specific immune response. Also provided herein are methods of treatment for autoimmune diseases, inflammatory diseases and cancer.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: September 28, 2021
    Assignees: Regents of the University of Minnesota, Diabetes-Free, Inc.
    Inventors: Bernhard J. Hering, Sabarinathan Ramachandran, Prashant Girinath
  • CD40 TARGETED PEPTIDES AND USES THEREOF
    Publication number: 20210070805
    Abstract: The present disclosure is related to compositions comprising peptides that bind CD40 and methods of use in inhibiting interaction of CD40 and CD154 and inducing immunosuppression. Provided herein are methods of transplantation and methods of inhibiting donor specific immune response. Also provided herein are methods of treatment for autoimmune diseases, inflammatory diseases and cancer.
    Type: Application
    Filed: November 4, 2020
    Publication date: March 11, 2021
    Inventors: Bernhard J. Hering, Sabarinathan Ramachandran, Prashant Girinath